(Q34189230)

31 July 2017

1 reference

title

Immune responses to ISCOM formulations in animal and primate models (English)

1 reference

Jean-Pierre Y Scheerlinck

31 July 2017

0 references

4

1 reference

31 July 2017

Sjölander A

1

1 reference

31 July 2017

Drane D

2

1 reference

31 July 2017

Maraskovsky E

3

1 reference

31 July 2017

Suhrbier A

5

1 reference

31 July 2017

Tennent J

6

1 reference

31 July 2017

Pearse M

7

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 March 2001

1 reference

31 July 2017

1 reference

31 July 2017

volume

19

1 reference

31 July 2017

issue

17-19

1 reference

31 July 2017

page(s)

2661-2665

1 reference

Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses.

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900497-7

7 January 2021

ISCOMs and other saponin based adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900497-7

7 January 2021

ISCOMs: an adjuvant with multiple functions

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900497-7

7 January 2021

Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS).

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900497-7

7 January 2021

Classical and new approaches to adjuvant use in domestic food animals

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900497-7

7 January 2021

Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM matrix

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900497-7

7 January 2021

Uptake and adjuvant activity of orally delivered saponin and ISCOM vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900497-7

7 January 2021

Preservation of mucosal and systemic adjuvant properties of ISCOMS in the absence of functional interleukin-4 or interferon-gamma.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900497-7

7 January 2021

The mucosal adjuvant effects of cholera toxin and immune-stimulating complexes differ in their requirement for IL-12, indicating different pathways of action

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900497-7

7 January 2021

Induction of lymphocyte recruitment in the absence of a detectable immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900497-7

7 January 2021

Monocyte and iscom enhancement of cell-mediated response to cytomegalovirus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900497-7

7 January 2021

Induction of protective immunity against influenza virus in a macaque model: comparison of conventional and iscom vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900497-7

7 January 2021

Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900497-7

7 January 2021

The role of type-1 and type-2 T-helper immune responses in HIV-1 vaccine protection.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900497-7

7 January 2021

beta-chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900497-7

7 January 2021

HIV-1 vaccine-induced immune responses which correlate with protection from SHIV infection: compiled preclinical efficacy data from trials with ten different HIV-1 vaccine candidates.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900497-7

7 January 2021

The major Epstein-Barr virus (EBV) envelope glycoprotein gp340 when incorporated into Iscoms primes cytotoxic T-cell responses directed against EBV lymphoblastoid cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900497-7

7 January 2021

Prospects for the development of new vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900497-7

7 January 2021

10.1016/S0264-410X(00)00497-7

Identifiers

DOI

1 reference

31 July 2017

1 reference